Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
The Journal of Pathology
|
July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition
Wei Zhou, Adrian M Jubb, Karen Lyle, et al.
Nature Communications
|
November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Medicinal Chemistry
|
March 12, 2016
Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Journal of Medicinal Chemistry
|
October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Cancer Discovery
|
September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Journal of Medicinal Chemistry
|
May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
James F Blake, Michael Burkard, Jocelyn Chan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 25, 2013
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant, Xiaolei Ma, Henry R Maun, et al.
Journal of Medicinal Chemistry
|
March 2, 2026
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C
Matthew L Landry, Sushant Malhotra, Maureen Beresini, et al.
Cell Reports. Medicine
|
January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Mahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 3, 2019
Disruption of IRE1α through its kinase domain attenuates multiple myeloma
Jonathan M Harnoss, Adrien Le Thomas, Anna Shemorry, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
The Journal of Pathology
|
July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition
Wei Zhou, Adrian M Jubb, Karen Lyle, et al.
Nature Communications
|
November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Medicinal Chemistry
|
March 12, 2016
Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Journal of Medicinal Chemistry
|
October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
Robert Heald, Krista K Bowman, Marian C Bryan, et al.
Cancer Discovery
|
September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Journal of Medicinal Chemistry
|
May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
James F Blake, Michael Burkard, Jocelyn Chan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 25, 2013
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant, Xiaolei Ma, Henry R Maun, et al.
Journal of Medicinal Chemistry
|
March 2, 2026
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C
Matthew L Landry, Sushant Malhotra, Maureen Beresini, et al.
Cell Reports. Medicine
|
January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Mahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 3, 2019
Disruption of IRE1α through its kinase domain attenuates multiple myeloma
Jonathan M Harnoss, Adrien Le Thomas, Anna Shemorry, et al.
Page
of 11